Ticker brief
NTRA NATERA INC
Consumer, Non-cyclical · Healthcare-Products
last close
$403.95
1 day
+0.6%
14 days
+0.8%
mkt cap
$40.0B
signals 14d
36
authors 14d
22
crowd 14d
-2.7σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 63% rich · 87 pctile own 1y | IV/HV 1.34× |
| Skew — 25Δ RR 30d | -0.021 64 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.85 elevated | 5-session Δ +0.17 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-06-25 (z=2.6) |
| Next earnings | 2026-11-05 (proj) | in 10d |
| CSP screen | rank #116 · $375.5 strike · 1.01% prem | on the CSP screen (2026-10-23) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-15 · now +0.25 (−1 bearish … +1 bullish)
Who spoke22
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @PrimeTrading_ | C | -2.18 | 7 | +0.44 |
| @cfromhertz | B | -0.96 | 4 | +0.39 |
| @OzmosiHealth | C | · | 3 | +0.17 |
| @equitydd | C | -1.08 | 2 | +0.10 |
| @BiopharmIQ | B | · | 2 | +0.05 |
| @bioinvestor24 | A | -0.87 | 2 | -0.70 |
| @nanalyzetweets | B | +5.59 | 1 | +0.20 |
| @Sebagyeong | C | -1.16 | 1 | +0.10 |
| @PatrickWalker56 | C | +1.71 | 1 | +0.65 |
| @AlexMarenco1 | C | -1.18 | 1 | +0.20 |
| @MonexUS_stock | C | +0.07 | 1 | +0.50 |
| @Leoskie_L | A | -1.21 | 1 | +0.35 |
| @AntonLaVay | A | -0.31 | 1 | +0.55 |
| @MartyChargin | C | -0.56 | 1 | +0.50 |
| @spluscollective | C | -0.98 | 1 | -0.10 |
| @KeithMcCullough | A | -3.03 | 1 | +0.80 |
| @EchoAnalysis | C | -0.85 | 1 | +0.20 |
| @BoxTraderVK | C | -0.97 | 1 | -0.10 |
| @ye4yn | B | -0.66 | 1 | +0.35 |
| @HedgeFundTips | B | +0.73 | 1 | +0.00 |
| @Biotech2k1 | A | +1.11 | 1 | -0.65 |
| @801010athlete | C | -0.84 | 1 | +0.20 |
Recent signals30of 36 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-15 | @PrimeTrading_ | +0.45 | Author identifies leading energy/software themes, weakening CRO-AI, and OKTA as the cleanest setup. | -0.2% | tweet ↗ |
| 2026-10-15 | @801010athlete | +0.20 | NTRA holds its 20-day EMA but has thin trading and overhead candle damage | -0.2% | tweet ↗ |
| 2026-10-15 | @OzmosiHealth | +0.10 | Natera's Signatera test was named to TIME's Best Inventions of 2026 list. | -0.2% | tweet ↗ |
| 2026-10-14 | @PrimeTrading_ | +0.55 | Maps sector leadership, deterioration and rotation while identifying NTRA as the top name to watch. | +2.3% | tweet ↗ |
| 2026-10-14 | @bioinvestor24 | -0.80 | Claims 90% of Natera blood-DNA cancer sequencing is unhelpful and wasteful. | +2.3% | tweet ↗ |
| 2026-10-14 | @bioinvestor24 | -0.60 | Argues personalized mRNA cancer vaccines are inexpensive and contrasts MRNA's scale with NTRA marketing. | +2.3% | tweet ↗ |
| 2026-10-14 | @cfromhertz | +0.45 | NTRA continues to trade well while holding October value-area support. | +2.3% | tweet ↗ |
| 2026-10-13 | @Biotech2k1 | -0.65 | Labels the named biotech stocks as bubble names and excludes them from bargains. | +2.1% | tweet ↗ |
| 2026-10-13 | @PrimeTrading_ | +0.35 | Maps leadership and rotation toward refiners, life-science tools, cyber and RF semis. | +2.1% | tweet ↗ |
| 2026-10-13 | @HedgeFundTips | +0.00 | Shares an equal-weight chart of biotech earnings estimates and revisions. | +2.1% | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.25 | Natera and TransCode will collaborate on a Phase 2a colorectal-cancer trial. | +2.1% | tweet ↗ |
| 2026-10-12 | @PrimeTrading_ | +0.50 | Maps sector leadership, cooling themes, and leading pullback setups. | +1.6% | tweet ↗ |
| 2026-10-11 | @ye4yn | +0.35 | Cross-sector ranking favors AI infrastructure, with PLTR and SNOW in the top ten and weaker names slated for review. | +0.8% | tweet ↗ |
| 2026-10-11 | @PrimeTrading_ | +0.40 | Maps leading themes and identifies semiconductor-equipment rotation and six technical setups. | +0.8% | tweet ↗ |
| 2026-10-10 | @BoxTraderVK | -0.10 | Monday watchlist gives technical levels and conditions without concrete entry intent. | +0.8% | tweet ↗ |
| 2026-10-10 | @equitydd | +0.20 | Reports the leading names from IBD's Top 50 list; extraction is capped at six tickers. | +0.8% | tweet ↗ |
| 2026-10-09 | @cfromhertz | +0.30 | MRNA is back near its highs while the broader genomics group is acting well. | +0.8% | tweet ↗ |
| 2026-10-08 | @PrimeTrading_ | +0.35 | Maps leadership and rotation into healthcare tools, genomics and semiconductors, highlighting DELL. | +3.4% | tweet ↗ |
| 2026-10-07 | @PrimeTrading_ | +0.50 | Maps sector leadership and rotation, highlighting six 21-day-structure setups. | +2.1% | tweet ↗ |
| 2026-10-07 | @EchoAnalysis | +0.20 | Avoids buying now and expects NTRA to enter a buy zone over 12–24 months. | +2.1% | tweet ↗ |
| 2026-10-07 | @KeithMcCullough | +0.80 | Buy more NTRA at this level. — Explicitly identifies the current level as a good place to add NTRA. | +2.1% | tweet ↗ |
| 2026-10-07 | @BiopharmIQ | +0.00 | Summarizes midday biotech news and associated stock moves for a broad list. | +2.1% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.15 | Natera announces a randomized Signatera-guided interventional melanoma study. | +2.1% | tweet ↗ |
| 2026-10-06 | @spluscollective | -0.10 | Discloses a recent TEM exit while questioning unexplained pullbacks across three stocks. | +0.8% | tweet ↗ |
| 2026-10-06 | @MartyChargin | +0.50 | Emphasizes sustained upside performance across four genomics stocks despite valuation concerns. | +0.8% | tweet ↗ |
| 2026-10-06 | @AntonLaVay | +0.55 | Presents TEM, NTRA and CAI as beneficiaries of downstream AI-biotech bottlenecks. | +0.8% | tweet ↗ |
| 2026-10-06 | @Leoskie_L | +0.35 | Separates oil-supply dynamics from a genomics basket driven by approvals, reimbursement and shipments. | +0.8% | tweet ↗ |
| 2026-10-06 | @MonexUS_stock | +0.50 | Highlights two Druckenmiller ideas and Natera's roughly 80% year-to-date rise. | +0.8% | tweet ↗ |
| 2026-10-05 | @AlexMarenco1 | +0.20 | Reports new index highs, distribution-day counts and 80%-100% exposure. | -5.1% | tweet ↗ |
| 2026-10-05 | @cfromhertz | +0.45 | End-of-day recap says genomic leaders led while technology and small caps also participated. | -5.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.